Three hundred tonnes. That is the volume of medical cannabis flower Germany's Federal Ministry of Health expects to import in 2026 — nearly ten times the 31.4 tonnes recorded in 2023, the last full year before medical cannabis was reclassified from a narcotic to a standard prescription medicine. For critics of Germany's progressive cannabis framework, that number is alarming. For clinicians and harm reduction advocates, it tells a different story entirely.

The number does not reveal a system being gamed. It reveals one being used — perhaps for the first time at a scale that reflects actual patient need.

From Narcotic to Prescription Medicine

Germany's legislative journey on medical cannabis began in earnest with the Cannabis as Medicine Act, which came into force in March 2017. For seven years, the Federal Institute for Drugs and Medical Devices (BfArM) tracked outcomes through an accompanying survey. What it found consistently was that patients reported either no side effects or only mild ones — a profile that compared favourably to many standard chronic-illness medications, including opioids. By April 2024, this evidence base had grown sufficient for legislators to act: medical cannabis was removed from Germany's Narcotics Act and reclassified as a prescription-only medicine, available only through licensed doctors.

No over-the-counter access. No vending machines. A licensed physician, a prescription, a pharmacy. The framework is stricter on access than many long-established medications — yet Germany's CDU-led Ministry of Health is now reportedly pushing to restrict telemedical prescribing and limit access to cannabis flowers specifically, citing concerns about abuse. Dr. Julian Wichmann, MD, Co-Founder and CEO of Bloomwell GmbH, one of Germany's largest medical cannabis platforms, has challenged that position directly in a widely circulated commentary for Business of Cannabis, arguing that no supporting clinical data or evidence of systematic abuse has been presented — only the import volume figures themselves.

What the Numbers Actually Show

Context dissolves the alarm. Germany has an estimated 20 million people who, based on disease prevalence data, could be eligible for medical cannabis therapy. Against that population, 300 tonnes looks less like oversupply and more like a system beginning to meet demand it has suppressed for years. As Wichmann's commentary puts it, from a health-protection perspective, import volumes have grown not too quickly but too slowly.

The argument is reinforced by prescription behaviour. In a 2026 survey of approximately 11,500 cannabis consumers in Germany, 53.7% reported medical motivations for their consumption. Yet only 29.2% said that pharmacy-sourced medical cannabis was their primary supply. The gap between medical intent and legal access is not narrow — it is the majority of medically motivated consumers who remain outside the system, sourcing from unregulated markets.

A comparable pattern appears in the UK. A 2026 study of 4,414 cannabis consumers found that only 12.9% held a medical cannabis prescription, while a further 35.9% reported medical use without one. Scientific surveys across multiple countries suggest that at least half of all cannabis consumers have medical motivations. The legal system, in each case, is serving a fraction of the population it was designed to help.

This is where the harm reduction argument becomes most concrete. A 2024 laboratory analysis by the Sanity Group — testing 300 samples of illegal cannabis obtained in Germany — found toxic pesticides in two-thirds of samples, and human faeces, bacteria, or viruses in approximately 65%. These are not edge cases. They are the baseline conditions of the unregulated supply chain that patients are forced to rely on when legal access is restricted or unaffordable.

Bloomwell's own patient survey data adds another dimension. Patients who accessed medical cannabis therapy through the platform reported significant reductions in their use of other prescription medications, including opioids — with the vast majority describing improved quality of life and work capacity as a result. In a September 2026 survey of 7,900 patients with experience of both the pharmacy and the illegal market, medical cannabis was rated higher on every safety and usability measure: transparency on active ingredients, product cleanliness, dosing clarity, and price. The illegal market, meanwhile, was identified as a significant source of stress.

A European Question, Not Just a German One

Germany's internal debate has implications beyond its borders. As the EU's most advanced medical cannabis market, Germany effectively sets a reference point for what progressive but responsible regulation looks like. A retreat from telemedicine access — restricting a tool that brings patients without easy transport links or specialist proximity into the system — would signal to other member states that expansion carries political risk. That signal matters in countries where medical cannabis frameworks are still forming.

In Malta, where medical cannabis operates under a separate regulatory framework from the adult-use Cannabis Harm Reduction Association (CHRA) model — the member-based, non-profit associations through which adults access cannabis under Chapter 628 of the Laws of Malta — the underlying dynamic is familiar. Our guide to Malta cannabis law outlines how the two systems differ in purpose and access pathways, but the tension between them is the same: patients with medical needs often navigate both frameworks, and restrictions in one push them toward the other, or toward the unregulated market. Harm reduction, by definition, requires keeping people inside regulated systems, not pushing them out.

The Real Risk

The genuine public health risk is not the one Germany's Ministry of Health appears to be focused on. It is not that too many patients are accessing safe, tested, physician-prescribed cannabis through a pharmacist. The risk is that policy retreats — restricting telemedical access, narrowing product categories, slowing prescription volumes — push medically motivated consumers back toward a supply chain that poisons two-thirds of its own product.

Import figures rising tenfold in three years are not evidence of a system failing. They are evidence of a system finally catching up with the population it was always meant to serve. Reframing them as proof of abuse, without presenting clinical data to support that claim, is not harm reduction. It is its opposite.

The real question, for Germany and for every European country watching its experience, is not how to slow the numbers down — but why it took this long to get here.

Sources:
Business of Cannabis — Legal Medical Cannabis Means Better, Not Weaker, Health Protection — https://businessofcannabis.com/legal-medical-cannabis-means-better-not-weaker-health-protection/

Featured image: Photo by Atlantic Ambience on Pexels

Share this article
The link has been copied!